Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

uniQure N.V.

http://www.uniqure.com

Latest From uniQure N.V.

BioMarin Gears Up To Give Roctavian Another Go

The company is aiming for an outcomes-based payment model in the US, while it is confident the gene therapy will fare better than some others have in Europe.

Business Strategies Companies

uniQure/CSL’s EtranaDez Could Take Lead Position In Hemophilia B Gene Therapy Market

The therapy could also face competition from players like Freeline, but new Phase III data position uniQure and CSL Behring well for planned FDA and EMA filings.

Gene Therapy Business Strategies

Accelerated Assessment Success In EU For CSL Behring And Roche

There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted. 

Review Pathway Gene Therapy

US Vs. EU: Is Cell And Gene Therapy Reimbursement Easier Stateside?

A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.

Gene Therapy Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Amsterdam Molecular Therapeutics (AMT)
    • InoCard GmbH
    • uniQure Germany GmbH
    • uniQure U.S.A.
    • uniQure The Netherlands
    • uniQure Inc.
UsernamePublicRestriction

Register